Acute lymphoblastic leukaemia: open trials in Norway

• NCT07476729

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  Trial Treatment · Phase 3 · Charite University, Berlin, Germany

  Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim

  Registry updated 2026-10-26

• NCT07297914

  Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

  Trial Treatment · Phase 2/3 · Bambino Gesù Hospital and Research Institute

  University Hospital, Oslo

  Registry updated 2026-10-20

• NCT05327894

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  Trial Treatment · Phase 3 · Princess Maxima Center for Pediatric Oncology

  Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · University Hospital Of North Norway HF, Tromsoe · St. Olavs hospital HF, Trondheim

  Registry updated 2026-10-19

• NCT05748171

  A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

  Trial Treatment · Phase 2 · Pfizer

  Oslo University Hospital HF, Oslo

  Registry updated 2026-09-24

• 2024-519320-24-00

  A Phase I/IIa study to assess the safety and biological activity of TdT-3, an autologous TCR T-cell therapy targeting TdT, in HLA-A*02:01+ patients aged ≥1 year with relapsed or refractory TdT+ acute leukemia or lymphoblastic lymphoma.

  Trial Treatment · Phase 1/2 · Oslo University Hospital HF

  Oslo University Hospital HF, Oslo

  Registry updated 2026-09-18

• NCT01949129

  Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

  Trial Treatment · Phase 2/3 · St. Anna Kinderkrebsforschung

  Oslo University Hospital HF, Oslo

  Registry updated 2026-09-04

• NCT03911128

  A Treatment Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  Research · Mats Heyman

  Haukeland University Hospital, Dept of Paediatrics, Bergen · Haukeland University Hospital, Dept of Haematology, Bergen · Oslo University Hospital, Dept of Haematology, Oslo · Oslo University Hospital, Dept of paediatric haemato- and oncology, Oslo · Stavanger University Hospital, Dept of Haematology, Stavanger · University Hospital of North Norway, Dept of Paediatrics, Tromsø · University Hospital North Norway, Dept of Haematology, Tromsø · St. Olavs University Hospital, Dept of Haematology, Trondheim · St. Olavs University Hospital, Dept of Paediatrics, Trondheim

  Registry updated 2026-08-13

• NCT04307576

  A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia

  Trial Treatment · Phase 3 · Mats Heyman

  Helse Bergen HF, Bergen · Oslo University Hospital HF, Oslo · Helse Stavanger HF, Stavanger · Universitetssykehuset Nord-Norge HF, Tromsoe · St. Olavs hospital HF, Trondheim

  Registry updated 2026-08-12

• 2025-522453-20-00

  Individualized Intrathecal Chemotherapy Based on Measurement of Brain Fluid Clearance in Pediatric Patients

  Trial Treatment · Phase 2 · Oslo University Hospital HF

  Oslo University Hospital HF, Oslo

  Registry updated 2026-08-04

• 2023-504694-20-00

  Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia

  Trial Treatment · Phase 1/2 · Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

  Oslo University Hospital HF, Oslo

  Registry updated 2026-06-04

• 2025-520982-39-00

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  Trial Treatment · Phase 3 · Universita Degli Studi Di Milano Bicocca

  Oslo University Hospital HF, Oslo · The University Hospital of North Norway (UNN), Tromsø · St. Olavs hospital HF, Trondheim

  Registry updated 2026-05-08

• NCT03590171

  International Study for Treatment of High Risk Childhood Relapsed ALL 2010

  Trial Treatment · Phase 2 · Charite University, Berlin, Germany

  Oslo University Hospital, Oslo

  Registry updated 2026-03-17

• NCT05658640

  HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

  Trial Treatment · Phase 1/2 · Princess Maxima Center for Pediatric Oncology

  Oslo University Hospital HF, Oslo

  Registry updated 2025-09-16

• NCT05745714

  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  Trial Treatment · Phase 1/2 · Princess Maxima Center for Pediatric Oncology

  Oslo University Hospital HF, Oslo

  Registry updated 2025-09-16

• NCT05751044

  HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  Trial Treatment · Phase 1/2 · Princess Maxima Center for Pediatric Oncology

  Oslo University Hospital HF, Oslo

  Registry updated 2025-09-16

All Acute lymphoblastic leukaemia trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error